Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday.

Aptose Biosciences Price Performance

NASDAQ:APTO opened at $0.14 on Thursday. Aptose Biosciences has a 12 month low of $0.14 and a 12 month high of $2.91. The firm has a market capitalization of $2.59 million, a PE ratio of -0.08 and a beta of 1.26. The business’s fifty day moving average price is $0.38 and its 200 day moving average price is $0.61.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.